Thyrocare Technologies Limited has reported robust financial results for the second quarter, accompanied by announcements of a bonus share issue and interim dividend.

Financial Performance

The diagnostic services provider posted a consolidated revenue of Rs 216.53 crore for Q2, marking a 22% year-on-year growth. The company's normalized EBITDA surged by 49% to Rs 75.36 crore, while profit after tax (PAT) jumped 82% to Rs 47.90 crore compared to the same quarter last year.

Key financial highlights for Q2:

The pathology segment, which forms the core of Thyrocare's business, grew by 24% year-on-year. Within this, franchise revenue increased by 20%, while partnership revenue saw a robust 35% growth.

Operational Highlights

Thyrocare processed 53.3 million tests during the quarter, up 21% from the previous year, reinforcing its position as India's largest diagnostic test volume processor. The company's active franchisee count stood at over 10,100, representing a 20% increase year-on-year.

Bonus Shares and Dividend

Celebrating its silver jubilee, Thyrocare's Board of Directors has approved and recommended a bonus issue of shares in the ratio of 2:1. This means shareholders will receive two new fully paid-up equity shares for every one share held.

Additionally, the Board declared an interim dividend of Rs 7 per equity share (70% of face value). The record date for dividend eligibility is set for October 24.

Management Commentary

Rahul Guha, Managing Director of Thyrocare Technologies, stated, "We are pleased to report a robust set of results for the quarter and the announcement of our bonus issue on the occasion of 25 years of Thyrocare coinciding with the auspicious occasion of Diwali. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics."

Future Outlook

Thyrocare continues to expand its presence across India, having added four new laboratories in Vijayawada, Bhagalpur, Roorkee, and Kashmir during the first half. The company remains committed to deepening its presence in underserved regions and scaling its franchise and partner channels.

With a strong balance sheet, including net cash and short-term investments exceeding Rs 190 crore, Thyrocare is well-positioned for future growth and expansion in the competitive diagnostics market.

Investors and analysts will be keenly watching how Thyrocare leverages its strong Q2 performance and strategic initiatives to drive sustained growth in the coming quarters.

Thyrocare Technologies , a leading diagnostics and preventive healthcare services provider, has reported robust financial results for the second quarter of the fiscal year. The company's performance showcases significant growth across key financial metrics, indicating strong operational efficiency and market demand for its services.

Financial Highlights

Profit and Revenue Growth

Thyrocare Technologies reported a consolidated net profit of ₹48.00 crore for the second quarter, representing a substantial 80% increase from ₹26.70 crore in the same period last year. This significant jump in profitability underscores the company's ability to effectively manage costs while expanding its operations.

The company's revenue also saw impressive growth, rising by 23% to ₹217.00 crore compared to ₹177.00 crore in the corresponding quarter of the previous year. This growth in revenue indicates strong demand for Thyrocare's diagnostic services and successful market penetration strategies.

Operational Efficiency

Thyrocare's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) showed a remarkable improvement, increasing to ₹71.35 crore from ₹48.29 crore in the previous year. This represents a growth of 47.80%, outpacing the revenue growth and suggesting enhanced operational efficiency.

The EBITDA margin expanded significantly to 32.95% from 27.23% in the previous year, an improvement of 570 basis points. This expansion in margin reflects the company's success in optimizing its operational costs and improving its overall profitability.

Market Position and Future Outlook

The strong financial performance in Q2 reinforces Thyrocare Technologies' position as a key player in the diagnostic services sector. The company's ability to grow its revenue and profitability at a faster pace than the overall market suggests it is gaining market share and benefiting from the increasing demand for quality healthcare diagnostics.

While the company has not provided specific guidance for the future, the robust Q2 results indicate a positive trajectory for Thyrocare Technologies. The sustained growth in revenue and the significant improvement in profitability metrics position the company well for continued success in the coming quarters.

Investors and market analysts will likely keep a close watch on Thyrocare's performance in the subsequent quarters to assess if this growth momentum can be maintained amidst evolving healthcare needs and market dynamics.

Note: All financial figures are in Indian Rupees (₹) and are on a consolidated basis.